Supported by high quality clinical outcomes

The HORIZON study: The largest, prospective, randomized, controlled MIGS pivotal trial to date

The first MIGS pivotal trial to enroll patients globally—556 patients at 38 centers in 9 countries
Clinical outcomes showed the largest improvement compared to cataract surgery alone for IOP reduction and medication elimination of any MIGS pivotal trial at 24 months.1-4,*

Hydrus Microstent treatment led to long-term IOP reduction

Proven, durable outcomes1
Compared to results with cataract surgery alone, the Hydrus Microstent treatment effect showed increased benefits from year 1 to year 2.

Treatment effect in the Hydrus Microstent group improved from year 1 to year 2 compared to cataract surgery alone.1

The Hydrus Microstent – delivering a new confidence in the treatment of mild to moderate primary open-angle glaucoma:

Superior long-term IOP reduction and glaucoma drop elimination

Clinically proven, 2-year outcomes showing the largest improvement compared to control for IOP reduction and elimination of glaucoma medication reported in a MIGS pivotal trial.1-4,*

Proven, durable outcomes

Treatment effect in the Hydrus Microstent group improved from year 1 to year 2 compared to cataract surgery alone.­1

Outstanding safety profile

Safety profile comparable with cataract surgery alone and other canal-based MIGS procedures.2-5,*

Straightforward and efficient microstent delivery

Intuitive delivery system allows for a straightforward procedure with minimal learning curve and no need to target collector channels or implant multiple devices.1,6

Read recent publications and abstracts to learn more about the Hydrus Microstent.